Immature teratoma with very high AFP levels

Rath, Abhipsa; Mitra, Subarna; Adhya, Amit Kumar; Majumdar, Saroj Kumar Das

doi:10.1016/j.eurox.2022.100170

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, the ovarian cancer molecular markers routinely detected in clinical practice are cancer antigen 125 (CA125) ( 12 ), carcinoembryonic antigen (CEA) ( 13 ), human epididymis protein 4 (HE4) ( 14 ), carbohydrate antigen 19-9 (CA19-9) ( 15 ), mesothelin ( 16 ), α-fetoprotein ( 17 ), PARP ( 18 ), FRα ( 19 ), TP53 ( 20 ), HRD ( 21 ), BRCA1/2 ( 22 ) and AXL ( 23 ) ( Table I ); however, the detection of only one of these markers often provides an inaccurate result ( 24 ). CA125 is the most frequently used biomarker in the diagnosis of ovarian cancer ( 25 ), while HE4 was introduced as a biomarker more recently.…”

Section: Diagnosismentioning

confidence: 99%

Ovarian cancer: Diagnosis and treatment strategies (Review)

Li,

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

Ovarian cancer is a malignant tumor that seriously endangers health. Early ovarian cancer symptoms are frequently challenging to detect, resulting in a large proportion of patients reaching an advanced stage when diagnosed. Conventional diagnosis relies heavily on serum biomarkers and pathological examination, but their sensitivity and specificity require improvement. Targeted therapy inhibits tumor growth by targeting certain characteristics of tumor cells, such as signaling pathways and gene mutations. However, the effectiveness of targeted therapy varies among individuals due to differences in their unique biological characteristics and requires individualized strategies. Immunotherapy is a promising treatment for ovarian cancer due to its long-lasting antitumor effect. Nevertheless, issues such as variable efficacy, immune-associated adverse effects and drug resistance remain to be resolved. The present review discusses the diagnostic strategies, rationale, treatment strategies and prospects of targeted therapy and immunotherapy for ovarian cancer.

show abstract

Section: Diagnosismentioning

confidence: 99%

Ovarian cancer: Diagnosis and treatment strategies (Review)

Li,

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

show abstract

Primary hepatoid adenocarcinoma of the lung with extremely elevated serum AFP: a case report and literature review

Cai,

Zhang,

Wang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Primary hepatoid adenocarcinoma of the lung (HAL) is an exceptionally rare subtype of lung cancer that mimics the morphology and biological behavior of hepatocellular carcinoma. Although reports in the literature are limited, HAL is known for its high malignancy and poor prognosis, thus drawing increasing attention. We present the case of a patient with a mass-like consolidation with central necrosis initially misdiagnosed as inflammation at another medical institution despite a percutaneous lung biopsy. After ineffective anti-inflammatory treatment, she was referred to our hospital. We performed another lung biopsy, obtaining five samples from different angles, and eventually diagnosed her with HAL. Surprisingly, her serum alpha-fetoprotein (AFP) levels were extraordinarily high, leading to the successful diagnosis of HAL. Here, we present a case report and a related literature review.

show abstract

Immature teratoma with very high AFP levels

Cited by 2 publications

References 4 publications

Ovarian cancer: Diagnosis and treatment strategies (Review)

Ovarian cancer: Diagnosis and treatment strategies (Review)

Primary hepatoid adenocarcinoma of the lung with extremely elevated serum AFP: a case report and literature review

Contact Info

Product

Resources

About